Eloralintide (LY3841136) is an investigational selective amylin-receptor agonist being studied for obesity and related conditions. Phase 2 findings and Phase 3 trials make it scientifically important, but it is not FDA-approved and no online product should be assumed equivalent to sponsor-manufactured trial material.
Eloralintide at a glance
| Development name | LY3841136 |
|---|---|
| Mechanism | Selective amylin-receptor agonist |
| U.S. status | Investigational; not FDA-approved |
| Human evidence | Phase 2 trial published; Phase 3 trials underway |
| Reviewed | August 11, 2026 |
What is amylin, and why is it studied?
Amylin is a hormone involved in metabolic signaling, including satiety and gastric function. Eloralintide is designed to selectively activate amylin receptors. This mechanism supports research interest but does not independently establish benefit, safety, or appropriate use.
What did the Phase 2 trial show?
A 48-week multicenter, randomized, double-blind, placebo-controlled study enrolled 263 adults in the United States with obesity or overweight plus a weight-related condition and without type 2 diabetes. Investigators reported weight-related efficacy and evaluated safety and tolerability. Interpretation should account for sample size, trial duration, sponsor involvement, discontinuation, and the lack of broad postmarketing experience.
What trials are underway?
ClinicalTrials.gov lists Phase 3 studies in adults with obesity or overweight, including populations with and without type 2 diabetes. Some studies extend into 2028. Until results are complete and regulators review an application, long-term safety and final labeling remain unsettled.
Eloralintide versus GLP-1 drugs
Eloralintide acts through amylin receptors rather than being another name for semaglutide or tirzepatide. Early studies and combination trials do not justify assuming equivalence, superiority, or interchangeability.
What people report online
Community-reported—not proof: interest centers on appetite, weight, possible combinations, and comparisons with incretin medicines. Because eloralintide is investigational, commercially sourced material carries additional identity and quality uncertainty.
Frequently asked questions
Is eloralintide FDA-approved?
No. Phase 3 status means it is being studied in larger trials; it does not mean approval has been granted.
Primary sources
- Published 48-week Phase 2 trial
- ClinicalTrials.gov: ENLIGHTEN-2 Phase 3 trial
- ClinicalTrials.gov: Phase 3 study without type 2 diabetes
Educational information only; not individualized medical advice or treatment instruction.
Leave a Reply